ARESTIN® promotes a healthier oral environment - long after your patient leaves your office - so healing can begin

Sustains a healthier balance of bacteria for 30 days

ARESTIN® delivers minocycline directly to infected pockets, providing safe, localized drug concentrations at the site of the infection. ARESTIN® stays in place and provides reduced bacterial levels, measurable even 30 days after treatment.

  • ARESTIN® maintains minimum inhibitory concentration (MIC) levels well above those required for common periodontal pathogens for up to 21 days.
  • Clinical trials show the use of ARESTIN® did not result in a significant increase of minocycline-resistant bacteria 2 months posttreatment.

Concentrations of minocycline in gingival crevicular fluid (GCF) at the site of administration

ARESTIN® shows significant reduction in periodontal bacteria after treatment

In susceptible individuals, the ongoing inflammatory process without intervention can cause loss of supporting tissue and, ultimately, teeth.

Periodontal disease is:

  • A persistent (and likely chronic) infection that can spread rapidly throughout the periodontium—it is caused by the presence of Gram-negative bacteria
  • The most common chronic bacterial infection in adults
  • The leading cause of adult tooth loss in the U.S.

For full safety information, click here.

Video not available

S. Smith, RDH
McLean, VA

View All Videos In Library »

ARESTIN® is indicated as an adjunct to scaling and root planing (SRP) procedures for reduction of pocket depth in patients with adult periodontitis. ARESTIN® may be used as part of a periodontal maintenance program, which includes good oral hygiene and SRP.

IMPORTANT SAFETY INFORMATION

ARESTIN® should not be used in any patient who has a known sensitivity to minocycline or tetracyclines. The use of drugs of the tetracycline class during tooth development may cause permanent discoloration of the teeth, and therefore should not be used in children or in pregnant or nursing women. Hypersensitivity reactions that included, but were not limited to, anaphylaxis, angioneurotic edema, urticaria, rash, swelling of the face and pruritus have been reported with the use of ARESTIN®. In clinical trials, the most frequently reported nondental treatment-emergent adverse events were headache, infection, flu syndrome and pain.

Please see Full Prescribing Information

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch, or call 1-800-FDA-1088.

Contact us with questions about your account or MyArestin.com